Literature DB >> 2868960

Multiple actions of anticholinesterase agents on chemosensitive synapses: molecular basis for prophylaxis and treatment of organophosphate poisoning.

E X Albuquerque, S S Deshpande, M Kawabuchi, Y Aracava, M Idriss, D L Rickett, A F Boyne.   

Abstract

The present study demonstrates that the reversible and irreversible anti-ChE agents have direct actions on the nicotinic acetylcholine receptor-ionic channel (AChR) and on the locust glutamatergic neuromuscular junction. In addition, the prophylaxis of lethality of organophosphorus anti-ChE compounds was studied. The lethality of VX and sarin was diminished when the rats were pretreated with physostigmine and atropine. The effectiveness of this protection, however, was markedly increased when a ganglionic blocker, either mecamylamine or chlorisondamine, was added, such that all the animals survived after receiving four times a lethal dose of VX. Pretreated animals receiving sarin showed significant recovery of morphological and functional properties of the neuromuscular junction as compared to the damage of structures from animals without pretreatment. Blood ChE inhibition was slightly decreased while brain and muscle AChE levels were significantly recovered (from 98 and 70% to 56 and 32%, respectively) by the pretreatment. This effect may partially explain the protection given by physostigmine but not that afforded by addition of a non-anti-ChE agent. Physostigmine, at concentrations greater than 20 microM, showed both a marked depression of the peak amplitudes of the endplate current (EPC) and a shortening of the decay time constants tau EPC. These effects were mostly due to a direct drug interaction with the nicotinic AChR blocking the ionic channel in its open conformation. Single-channel recordings showed that physostigmine decreases conductance and open times of the channels activated in the presence of ACh and in addition has an agonistic property on the nicotinic AChR. VX, on the other hand, only shortened the open times of ACh-activated channels without affecting the conductance. No agonist property was detected with VX. On glutamatergic synapses, the ChE inhibitors generated spontaneous firing of end-plate potentials (EPPs) and action potentials (APs). This effect was blocked in the presence of low external Ca2+ concentration or tetrodotoxin. It seems that the spontaneous EPP and AP firing resulted from an increased transmitter release induced by an increase in Na+ influx at the presynpatic nerve terminal. Physostigmine and some irreversible ChE inhibitors (VX and DFP) also blocked the postjunctional glutamate receptors. Similar to the nicotinic AChR, this effect was mostly related to a blockade of the open channels. In conclusion, the present studies showed significant protection of rats by physostigmine in combination with some ganglionic antagonists against lethality by organophosphate agents.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2868960     DOI: 10.1016/0272-0590(85)90129-0

Source DB:  PubMed          Journal:  Fundam Appl Toxicol        ISSN: 0272-0590


  11 in total

1.  Effects of organophosphorus anticholinesterases on nicotinic receptor ion channels at adult mouse muscle endplates.

Authors:  J E Tattersall
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

2.  Animal models that best reproduce the clinical manifestations of human intoxication with organophosphorus compounds.

Authors:  Edna F R Pereira; Yasco Aracava; Louis J DeTolla; E Jeffrey Beecham; G William Basinger; Edgar J Wakayama; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2014-06-06       Impact factor: 4.030

Review 3.  Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead.

Authors:  A R Satvik Iyengar; Abhay H Pande
Journal:  Protein J       Date:  2016-12       Impact factor: 2.371

4.  Pretreatment of Guinea pigs with galantamine prevents immediate and delayed effects of soman on inhibitory synaptic transmission in the hippocampus.

Authors:  Elena A Alexandrova; Yasco Aracava; Edna F R Pereira; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2010-06-16       Impact factor: 4.030

5.  Galantamine counteracts development of learning impairment in guinea pigs exposed to the organophosphorus poison soman: clinical significance.

Authors:  Jacek Mamczarz; Girish S Kulkarni; Edna F R Pereira; Edson X Albuquerque
Journal:  Neurotoxicology       Date:  2011-07-19       Impact factor: 4.294

6.  Acute toxicity of organophosphorus compounds in guinea pigs is sex- and age-dependent and cannot be solely accounted for by acetylcholinesterase inhibition.

Authors:  William P Fawcett; Yasco Aracava; Michael Adler; Edna F R Pereira; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2008-11-04       Impact factor: 4.030

7.  Molecular and cellular actions of galantamine: clinical implications for treatment of organophosphorus poisoning.

Authors:  Edna F R Pereira; Yasco Aracava; Manickavasagom Alkondon; Miriam Akkerman; Istvan Merchenthaler; Edson X Albuquerque
Journal:  J Mol Neurosci       Date:  2009-08-19       Impact factor: 3.444

8.  A single in vivo application of cholinesterase inhibitors has neuron type-specific effects on nicotinic receptor activity in guinea pig hippocampus.

Authors:  Manickavasagom Alkondon; Yasco Aracava; Edna F R Pereira; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2008-10-08       Impact factor: 4.030

9.  Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine.

Authors:  Yasco Aracava; Edna F R Pereira; Miriam Akkerman; Michael Adler; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2009-09-09       Impact factor: 4.030

10.  Modeling study of mecamylamine block of muscle type acetylcholine receptors.

Authors:  Konstantin Ostroumov; Asya Shaikhutdinova; Andrey Skorinkin
Journal:  Eur Biophys J       Date:  2007-10-16       Impact factor: 1.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.